Strategic partnerships Leverage StemBioSys proximity to UTHSC-SA and existing collaborations (GenCure, VWR) to forge co-development, manufacturing, or distribution agreements that accelerate market access for CELLvo Matrix powered products and hiPSC-derived cells.

Clinical-grade potential Position CELLvo Matrix and culture system for cGMP-scale expansion and delivery of stem cells and difficult-to-culture cells in research-to-therapeutic workflows, targeting contract manufacturing, regenerative medicine, and diagnostic applications.

New product opportunities Capitalize on recent CELLvo product launches such as CELLvo Atrial Cardiomyocytes to pursue adjacent chamber-specific or lineage-specific cell products, expanding into cardiac research tools, disease modeling, and personalized medicine services.

Funding and growth Highlight ongoing fundraising history and recent leadership changes to engage strategic investors and partners focused on biomanufacturing, cell therapy, and scalable biotech platforms with potential co-investment or license arrangements.

Scale and quality Emphasize capacity expansion via a completed cGMP facility build-out to attract pharma/biotech collaborators seeking compliant, scalable stem cell culture systems, with emphasis on quality standards and regulatory alignment.